Eisai Co., Ltd. will acquire MGI Pharma for approximately $3.9 billion in an all-cash transaction. The acquisition has been unanimously approved by MGI’s board; it is expected to occur by means of a tender offer followed by a cash merger, is subject to customary closing conditions and regulatory approvals, and is expected to be completed during the first quarter of 2008. According to a press statement, Eisai “expects MGI’s marketed and pipeline products in oncology and acute...